Compare YOUL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YOUL | TCRX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 49.4M |
| IPO Year | 2024 | 2021 |
| Metric | YOUL | TCRX |
|---|---|---|
| Price | $0.50 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 175.7K | ★ 391.2K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.29 | $0.72 |
| 52 Week High | $4.40 | $2.57 |
| Indicator | YOUL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | N/A |
| Support Level | $0.49 | N/A |
| Resistance Level | $0.54 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 77.22 | 0.00 |
Youlife Group Inc is a blue-collar lifetime service platform in China, dedicated to serving the needs throughout the entire life cycle of the blue-collar talent. It provides blue-collar lifetime services to students, blue-collar talent, and corporate customers. Its segments are the vocational education segment, which engages in the provision of vocational education entrusted management services, self-operated vocational school services, and Others; the HR recruitment segment engages in the provision of HR recruitment services regarding blue-collar talent to customers; the employee management segment engages in the provision of labor outsourcing services, labor dispatch services and others; and the market service segment engages in the provision of value-added services.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.